Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient-Centered Study of Trastuzumab Deruxtecan (T-DXd) in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management Reflecting Real-World Clinical Practice

NCT07371585 is registered in ClinicalTrials.gov with SOLTI Breast Cancer Research Group as lead sponsor.

NCT NCT07371585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07371585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patient-Centered Study of Trastuzumab Deruxtecan (T-DXd) in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management Reflecting Real-World Clinical Practice
Lead sponsor
SOLTI Breast Cancer Research Group
Phase
Phase 2
Overall status
Recruiting
Start date
February 18, 2026
Completion date
July 1, 2030
Enrollment
300 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage iv